Upadacitinib Oral Solution(艾伯维)

乌帕替尼口服溶液（AbbVie）

Report date: 2025/09/10 14:49:51

Base Information

Drug NameUpadacitinib Oral Solution(艾伯维)
Drug Alias NameUpadacitinibum乌西替尼Upadacitinib tartrate乌帕替尼口服溶液（2.2类改良型）Upadicitinib hemihydrate +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK1 inhibitors
TargetsTyrosine-protein kinase JAK1
Therapy Area/IndicationsNon-radiographic axial spondyloarthritisPolyarticular Juvenile Idiopathic ArthritisDermatitis, Atopic +[9] 
Global Approved IndicationsNon-radiographic axial spondyloarthritisPolyarticular Juvenile Idiopathic ArthritisDermatitis, Atopic +[8] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/04/26
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbbvie Inc
Inactive CompaniesN/A
Active IndicationsNon-radiographic axial spondyloarthritisPolyarticular Juvenile Idiopathic ArthritisDermatitis, Atopic +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG